It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

Over three years af­ter the first re­jec­tion and less than three months af­ter the last one, No­var­tis has fi­nal­ly earned FDA ap­proval for its biosim­i­lar to Am­gen’s $4 bil­lion can­cer drug Neu­las­ta. And they’re call­ing it Ziex­ten­zo.

Un­like the 2016 and 2019 re­jec­tions — both of which the Swiss gi­ant tucked in as a line item on a quar­ter­ly re­port — No­var­tis an­nounced the ap­proval in a state­ment Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER